The global market for complicated urinary tract infections treatment is poised for impressive growth over the next decade, with projections indicating a significant upward trend. Valued at over USD 9.2 billion in 2023, the market is expected to reach USD 16.1 billion by 2033, reflecting a robust Compound Annual Growth Rate (CAGR) of 5.76% during the forecast period.
This growth is driven by the increasing incidence of complicated UTIs, exacerbated by the growing challenge of drug-resistant bacteria and the overuse of antibiotics. Healthcare providers are increasingly turning to quinolones and cephalosporins as critical treatment options for managing severe infection cases, especially where resistance to standard treatments is present.
Despite the market’s promising outlook, the lack of consensus on treatment guidelines remains a significant challenge. Conflicting recommendations from healthcare organizations can create confusion and hinder the adoption of effective treatment protocols, potentially slowing market growth.
As demand for more effective solutions rises, collaboration between healthcare providers, pharmaceutical companies, and regulatory bodies will be crucial. By aligning on treatment guidelines and exploring innovative therapeutic modalities, the industry can better address the complexities of cUTIs, ultimately ensuring improved patient outcomes.
Key Takeaways:
- North America is projected to lead the market of complicated urinary tract infections with an estimated market value of USD 5.29 billion by end of the forecast period.
- The market in East-Asia is expected to witness fastest CAGR of 5.1% while possessing 20% market share by end of 2033.
- By drug class, Penicillin and combinations is expected witness fastest segment growth of 7.9% during the forecast period.
- Quinolones segment is expected to possess hegemony with 48.6% market share by end of the forecast period.
- By distribution channel, hospital pharmacies is anticipated to dominate market with 51% market share by 2033.
“The projected growth of the global cUTIs treatment market underscores the urgent need for effective strategies to combat the rising incidence of drug-resistant bacteria,” stated a representative from FMI. “Moreover, streamlining treatment protocols and overcoming discrepancies in clinical guidelines will be essential to addressing the challenges faced by healthcare providers.”
Explore the Growing Demand for Complicated Urinary Tract Infections treatment: Get All the Insights in Our Comprehensive Report!
Competitive Landscape:
The global Complicated Urinary Tract Infections treatment market is highly competitive due to presence of large number of players and innovative product offerings. In addition, business expansion activities through partnerships and agreements are factors expected to further increase the competition. The major players in the market are:
- Spero Therapeutics
- Wockhardt
- Venatorx Pharmaceuticals
- Allecra Therapeutics
- Nabriva Therapeutics AG
- MerLion Pharmaceuticals
- Allergan
- Bayer AG
- Pfizer, Inc
- GlaxoSmithKline plc
- Bristol-Myers Squibb Company
- Janssen Global Services, LLC
Some Recent Developments In This Industry Are:
- In November 2020, Allergan announced FDA acceptance of Supplemental New Drug Indication for Avycaz for the treatment of patients with complicated Urinary Tract Infections (cUTI) and complicated Intra-abdominal Infections (cIAI).
- In October 2021, Spero Therapeutics Inc. submitted a new drug application (NDA) to the US Food and Drug Administration (FDA), seeking approval for tebipenem HBr tablets for the treatment of complicated urinary tract infections (cUTI), including pyelonephritis, caused by susceptible microorganisms.
- In September 2021, BDR Pharma, one of India’s leading generic pharmaceutical companies, launched biapenem to treat patients with intra-abdominal infections, lower respiratory infections, or complicated urinary tract infections.
Key Segments Profiled in the Complicated Urinary Tract Infections treatment Industry survey:
Complicated Urinary Tract Infections treatment market by Drug class:
- Penicillin and combinations
- Quinolones
- Cephalosporin
- Azoles and Amphotericin B
- Nitro furans
Complicated Urinary Tract Infections treatment market by Distribution channel:
- Hospital Pharmacies
- Gynecology and Urology Clinics
- Drug stores
- Retail Pharmacies
Complicated Urinary Tract Infections treatment market by Region:
- North America
- Latin America
- Europe
- South Asia
- East Asia
- Oceania
- Middle East and Africa
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-347-918-3531
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube
